A disrupted protein degradation process in heart muscle cells can lead to a range of severe heart diseases. In the case of ...

Mineralys Therapeutics (MLYS) has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...

Announcing a new article publication for BIO Integration journal. As altitude increases, the partial pressure of oxygen will ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

Stanford researchers introduced affordable gene-editing kits ready for the classroom, aiming to make the field more accessible for high school students.

Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...

Disinfectants induce oxidative damage in bacteria, but a single mutation triggers the expression of genes that help the ...

A team of biomolecular engineers, pathologists, and internal medicine specialists at the University of Texas Medical Branch, ...

By creating gene editors not found in nature, or optimizing existing editors, AI can improve the accuracy, effectiveness, and accessibility of gene editing.

Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio— have products in the pipeline that could ...

NGS revenue guidance was raised to $205 million to $209 million, reflecting 21%-24% growth. Biopharma revenue was guided to $23 million for fiscal 2025, representing 13% year-over-year growth.